MA54939A - Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 - Google Patents

Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2

Info

Publication number
MA54939A
MA54939A MA054939A MA54939A MA54939A MA 54939 A MA54939 A MA 54939A MA 054939 A MA054939 A MA 054939A MA 54939 A MA54939 A MA 54939A MA 54939 A MA54939 A MA 54939A
Authority
MA
Morocco
Prior art keywords
hydroxypyridoxazepines
nrf2 activators
nrf2
activators
hydroxypyridoxazepines used
Prior art date
Application number
MA054939A
Other languages
English (en)
Inventor
Mark Elban
Michal Pawel Glogowski
Michael Clinton Koetting
Brian Griffin Lawhorn
Jay M Matthews
Jaclyn Renee Patterson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA54939A publication Critical patent/MA54939A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054939A 2019-02-15 2020-02-11 Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 MA54939A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806201P 2019-02-15 2019-02-15
US201962931877P 2019-11-07 2019-11-07

Publications (1)

Publication Number Publication Date
MA54939A true MA54939A (fr) 2021-12-22

Family

ID=69726636

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054939A MA54939A (fr) 2019-02-15 2020-02-11 Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2

Country Status (16)

Country Link
US (1) US11945826B2 (fr)
EP (1) EP3924356A1 (fr)
JP (1) JP2022520442A (fr)
KR (1) KR20210126676A (fr)
CN (2) CN118206566A (fr)
AU (1) AU2020222080C1 (fr)
BR (1) BR112021016042A2 (fr)
CA (1) CA3129955A1 (fr)
CL (1) CL2021002110A1 (fr)
CO (1) CO2021010930A2 (fr)
IL (2) IL285438B1 (fr)
MA (1) MA54939A (fr)
MX (1) MX2021009659A (fr)
SG (1) SG11202108257TA (fr)
TW (1) TWI843806B (fr)
WO (1) WO2020165776A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3833662T3 (da) 2018-08-20 2024-02-26 Janssen Pharmaceutica Nv Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020283361A1 (en) 2019-05-31 2022-01-20 Ube Corporation Benzotriazole derivative
CN118488944A (zh) 2022-01-07 2024-08-13 中外制药株式会社 具有Nrf2活化作用的含氮杂环化合物
WO2023210741A1 (fr) * 2022-04-28 2023-11-02 第一三共株式会社 Composé benzotriazole
TW202345792A (zh) * 2022-04-28 2023-12-01 日商第一三共股份有限公司 苯并噻吩化合物
WO2024047248A1 (fr) * 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Utilisation d'activateurs de nrf2 pour le traitement de la maladie des petits vaisseaux cérébraux

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670099A1 (fr) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthese et activites biologiques de nouveaux composes tricycliques-bis-enones (tbe)
CA2934216C (fr) * 2013-12-18 2021-03-16 Glaxosmithkline Intellectual Property Development Limited Derives de phenyle ou depropionate de benzyle substitues et leurs compositions pharmaceutiques utiles en tant que regulateurs du facteur nucleaire erythroide 2 (nrf2)
CA2988374A1 (fr) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Regulateurs de nrf2
CA2988373A1 (fr) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Regulateurs de nrf2
MX2017016405A (es) 2015-06-15 2018-05-22 Glaxosmithkline Ip Dev Ltd Reguladores de nrf2.
JP6761805B2 (ja) * 2015-08-12 2020-09-30 持田製薬株式会社 イソチアゾール誘導体
WO2017060854A1 (fr) * 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles utilisés comme régulateurs de nrf2
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
JP2020500918A (ja) * 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール
US11078216B2 (en) * 2016-12-14 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as NRF2 activators
JP7110197B2 (ja) 2016-12-15 2022-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎｒｆ２アクチベーター

Also Published As

Publication number Publication date
AU2020222080C1 (en) 2022-09-29
US11945826B2 (en) 2024-04-02
IL285438A (en) 2021-09-30
IL285438B1 (en) 2024-08-01
WO2020165776A1 (fr) 2020-08-20
BR112021016042A2 (pt) 2021-10-05
US20220204526A1 (en) 2022-06-30
KR20210126676A (ko) 2021-10-20
CN113474349A (zh) 2021-10-01
IL313950A (en) 2024-08-01
CL2021002110A1 (es) 2022-02-11
TWI843806B (zh) 2024-06-01
SG11202108257TA (en) 2021-08-30
MX2021009659A (es) 2021-09-08
CO2021010930A2 (es) 2021-09-09
CA3129955A1 (fr) 2020-08-20
TW202045514A (zh) 2020-12-16
AU2020222080A1 (en) 2021-09-02
CN118206566A (zh) 2024-06-18
EP3924356A1 (fr) 2021-12-22
CN113474349B (zh) 2024-03-01
JP2022520442A (ja) 2022-03-30
AU2020222080B2 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MA54939A (fr) Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA50589A (fr) Compositions de pyrrolopyrrole en tant qu'activateurs de pyruvate kinase (pkr)
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
ITUA20161510A1 (it) Composizione per colorare la fibra cheratinica
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma